579 related articles for article (PubMed ID: 9291241)
21. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.
Phillips DR; Teng W; Arfsten A; Nannizzi-Alaimo L; White MM; Longhurst C; Shattil SJ; Randolph A; Jakubowski JA; Jennings LK; Scarborough RM
Circulation; 1997 Sep; 96(5):1488-94. PubMed ID: 9315536
[TBL] [Abstract][Full Text] [Related]
22. [Glycoprotein IIb/IIIa antagonist eptifibatide in acute coronary syndrome without elevation of ST segment].
Mazaev AA; Naĭmushin IaA; Ruda MIa
Kardiologiia; 2006; 46(3):49-55. PubMed ID: 16710256
[TBL] [Abstract][Full Text] [Related]
23. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
[TBL] [Abstract][Full Text] [Related]
24. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
25. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
[TBL] [Abstract][Full Text] [Related]
26. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
Plosker GL; Ibbotson T
Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
Tardiff BE; Jennings LK; Harrington RA; Gretler D; Potthoff RF; Vorchheimer DA; Eisenberg PR; Lincoff AM; Labinaz M; Joseph DM; McDougal MF; Kleiman NS;
Circulation; 2001 Jul; 104(4):399-405. PubMed ID: 11468200
[TBL] [Abstract][Full Text] [Related]
28. Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Curran MP; Keating GM
BioDrugs; 2006; 20(1):63-5. PubMed ID: 16573353
[TBL] [Abstract][Full Text] [Related]
29. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Harrington RA
Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233
[TBL] [Abstract][Full Text] [Related]
30. Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.
Fintel DJ; Ledley GS
Clin Cardiol; 2000 Sep; 23 Suppl 5(Suppl 5):V1-12. PubMed ID: 11019716
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
[TBL] [Abstract][Full Text] [Related]
32. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Mahaffey KW; Harrington RA; Simoons ML; Granger CB; Graffagnino C; Alberts MJ; Laskowitz DT; Miller JM; Sloan MA; Berdan LG; MacAulay CM; Lincoff AM; Deckers J; Topol EJ; Califf RM
Circulation; 1999 May; 99(18):2371-7. PubMed ID: 10318656
[TBL] [Abstract][Full Text] [Related]
33. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
34. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.
Dyke CM; Bhatia D; Lorenz TJ; Marso SP; Tardiff BE; Hogeboom C; Harrington RA
Ann Thorac Surg; 2000 Sep; 70(3):866-71; discussion 871-2. PubMed ID: 11016325
[TBL] [Abstract][Full Text] [Related]
35. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
[TBL] [Abstract][Full Text] [Related]
36. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
Fernandes LS; Tcheng JE; O'Shea JC; Weiner B; Lorenz TJ; Pacchiana C; Berdan LG; Maresh KJ; Joseph D; Madan M; Mann T; Kilaru R; Hochman JS; Kleiman NS;
J Am Coll Cardiol; 2002 Sep; 40(6):1085-91. PubMed ID: 12354432
[TBL] [Abstract][Full Text] [Related]
37. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
[TBL] [Abstract][Full Text] [Related]
38. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
Campbell KR; Ohman EM; Cantor W; Lincoff AM
Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178
[TBL] [Abstract][Full Text] [Related]
39. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.
Tricoci P; Newby LK; Kandzari DE; Harrington RA
Expert Rev Cardiovasc Ther; 2007 May; 5(3):401-12. PubMed ID: 17489665
[TBL] [Abstract][Full Text] [Related]
40. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
